Compare Expensify Inc (EXFY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs BIO-TECHNE Corp — how do they compare? Expensify Inc trades at $2.33 (market cap $224.32M), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 50.1× Expensify Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Expensify Inc pays none. Which is the better fit depends on your goals.
| EXFY | TECH | |
|---|---|---|
Market Cap | $224.32M | $11.24B |
Sector | Technology | Health |
52-Week High | $2.69 | $72.29 |
52-Week Low | $0.75 | $43.31 |
Enterprise Value | $163.94M | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.69, up 35.86% in 24 hours, with a bullish technical signal from moving averages but overbought RSI levels. The company reported Q2 2026 revenue of $33.9 million, beating EPS estimates, and raised free cash flow guidance. Despite negative net margins, cash flow from operations improved to $20.09 million in 2025, and the balance sheet shows $48.77 million in cash with low debt.
The outlook is cautiously optimistic due to earnings beats and AI-driven growth initiatives, but high P/E of 258.82 and persistent losses pose valuation risks. Analyst consensus is split between Buy and Hold, reflecting uncertainty over profitability sustainability amid competitive pressures.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
